Companies › VelaVigo Bio
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VBC101 | – | Phase 1 | Participants With Advanced Solid Tumor Malignancies | Jul 2027 |
| VBC103 | – | Phase 1 | Participants With Advanced Solid Tumor Malignancies | Dec 2027 |
| VBC108 | – | Phase 1 | Advanced Solid Tumors | Jul 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07136779 | VBC101 | Phase 1 | Participants With Advanced Solid Tumor Malignancies | Oncology | Jul 2027 |
| NCT07299747 | VBC103 | Phase 1 | Participants With Advanced Solid Tumor Malignancies | Oncology | Dec 2027 |
| NCT07700160 | VBC108 | Phase 1 | Advanced Solid Tumors | Oncology | Jul 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.